Italia markets closed
Dow Jones
38.586,11 -3,05 (-0,01%) Nasdaq
17.718,59 +29,70 (+0,17%) Nikkei 225
38.102,44 -712,12 (-1,83%) EUR/USD
1,0724 +0,0015 (+0,14%) Bitcoin EUR
61.017,27 -1.114,14 (-1,79%) CMC Crypto 200
1.369,44 -18,72 (-1,35%)
NBIX Sep 2024 145.000 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 03:56PM EDT. Mercato aperto.
| Chiusura precedente | 9,00 |
| Aperto | 9,00 |
| Denaro | 7,10 |
| Domanda | 10,80 |
| Prezzo d'esercizio | 145,00 |
| Scadenza | 2024-09-20 |
| Min-Max giorno | 9,00 - 9,00 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 94 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.